Methods for cell expansion
The perfusion plate meander bioreactor system effectively expands cells with high CD8+ and CD56+ profiles and low CD3+ antibodies, addressing cost and efficiency issues in existing methods by using interleukin 12 and antibody 4-1BB, and real-time monitoring to optimize culture conditions.
Patent Information
- Application Number
- DE102023002417
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-06-15
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2043-06-15
AI Technical Summary
Existing methods for expanding non-adherently growing cells, such as invariant T lymphocytes and NK cells, particularly tumor-infiltrated NK cells and mucosa-associated invariant T cells (MAIT), face challenges in achieving high proportions of CD8+ and CD56+ antibodies with low CD3+ antibodies, and are hindered by high costs associated with human serum use.
The method employs a perfusion plate meander bioreactor with a culture medium flow system that includes interleukin 12 or a mixture of interleukin 2 and 12, and antibody 4-1BB, using a laminar flow and controlled gas diffusion to expand cells with a high proportion of CD8+ and CD56+ antibodies, while minimizing CD3+ antibodies, and incorporates indicator beads for real-time monitoring and adjusting conditions.
This approach enables efficient expansion of cells with desired antigen profiles and reduces costs by optimizing culture conditions, leading to higher yields and faster treatment readiness with lower serum usage.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[0001] The invention describes a method for expanding cells, such as non-adherent cells, non-adherent T lymphocytes or NK cells, but also other immune cells, e.g., tumor-infiltrated NK cells (TINK) and mucosa-associated invariant T cells (MAIT) with high proportions of CD8+ and CD56+ antibodies, but also with a low proportion of CD3+ antibodies, in a perfusion-plate meander bioreactor.
[0002] T cells known to possess a single invariant TCR are NKT cells and MAIT cells. The important role NKT cells play in protecting an individual against bacteria and cancer, as well as their involvement in the pathology of an autoimmune disease, was primarily elucidated through a study in mice. Meanwhile, MAIT cells exist in large numbers in human peripheral blood, the intestine, and the liver, and they play a crucial role in mucosal immunity, but many of the details remain unclear. Although MAIT cells are abundant in humans, producing large quantities of them, which depends on their preparation from a living human host, is limited because MAIT cells are difficult to proliferate.MAIT cells must be obtained by preparation from a living body and purification, and there is neither a method for inducing differentiation in vitro / amplification nor a technology relating to character analogous cells (model cells).
[0003] EP 38 38 288 A1 describes a composition for expanding lymphocytes, comprising at least two types of cytokines selected from interleukin-2 (IL-2), interleukin-15 (IL-15), and interleukin-21 (IL-21). The invention further relates to a method for producing a population of clinically relevant lymphocytes, comprising the steps of: obtaining a body sample from a mammal, in particular a tissue sample or a body fluid sample, comprising at least one lymphocyte, and optionally separating the cells in the body sample; culturing the body sample in vitro to expand and / or stimulate lymphocytes in the sample, wherein the cultivation comprises the use of IL-2, IL-15, and / or IL-21, and optionally determining the presence of a clinically relevant lymphocyte in the cultured sample. The present invention also relates to immunotherapy and the population of clinically relevant lymphocytes.The T cell was preferably selected from a mucosal-associated invariant T cell (MAIT). Aphaeresis was performed on a healthy donor prepared with NY-ESO-1. After separation of the blood components, the product containing the leukocytes was separated from the remainder. The cells were suspended in Cellgro, consisting of 5% pooled human AB serum, 1000 U / ml IL-2, 10 ng / ml IL-15, and 10 ng / ml IL-21. The medium additionally contained 10 µmol of NY-ESO-1 peptide as an expansion antigen. The expansion of lymphocytes from peripheral blood involved the step of stimulation with irradiated autologous PBMCs pulsed with the antigen of interest. Autologous PBMCs were pulsed with 10 mM NY-ESO-1 peptide at RT for two hours and then irradiated with 55 Gy.Pulsed irradiated autologous PBMCs were added to the lymphocyte culture on day 7 and resuspension in fresh culture medium, supplemented with 5% pooled human antibiotic serum containing cytokines at the concentrations defined above. On day 10, the cells were expanded with Cellgro, supplemented with 5% pooled human antibiotic serum and cytokines. OKT3 antibodies at a concentration of 30 ng / ml were added to the same culture medium as described above, along with irradiated feeder cells (55 Gy) at a 1:10 (feeder cell:T cell ratio) to the peptide and cytokines. On days 17 to 20 of culture, the cells were harvested for analysis or administered to the patient. Pancreatic tumor tissue is harvested directly after surgery and placed in a sterile container. The tumor tissue is then cut into 1- to 2-mm pieces using a sterile scalpel. 3Tissue was sectioned. Each tissue piece was to be transferred into a well of a 24-well plate. 1 ml of RPMI 1640 culture medium containing 10% fetal bovine serum was added to each well. The medium was changed on days 7 and 14, meaning the culture medium was removed and replaced with fresh culture medium of the same type. When the tumor cells reached a very high density, the culture was transferred to a 96-well plate.
[0004] The invention according to WO 2019 180 270 A1 provides engineered lymphocytes (e.g., γδ T cells, NK cells, NK-like T cells, engineered inborn lymphocytes, or MAIT cells) containing a heterologous targeting construct lacking an intracellular signaling domain capable of activating the lymphocyte on which the construct is expressed. For example, in some embodiments, PBMCs are pre-enriched using magnetic bead sorting, which can yield more than 90% γδ T cells. These cells can be cultured in gas-permeable bioreactor bags for up to 21 days or longer in the presence of one or more factors (e.g., TCR agonists, co-receptor agonists, and / or cytokines, such as IL-4, IL-15, and / or IFN-γ). Variations of this method and other methods for obtaining Vδ1-T cells are suitable as part of the present invention.For example, Vδ1 T cells obtained from blood can alternatively be obtained using other methods.
[0005] US 2019 382 725 describes systems and methods for modulating the function of mucosa-associated invariant T cells (MAITs) in the absence of T-cell receptor (TCR) signaling. These systems and methods can be used to elucidate MAIT cell function and evaluate potential therapeutic strategies for inflammatory diseases. Mononuclear cells, generally including monocytes and lymphocytes, can be obtained from blood, peripheral blood, bone marrow, umbilical cord blood, mucosal tissue, the gastrointestinal tract, liver, and lungs. Mononuclear cells can be obtained using established methods such as centrifugation, magnetic bead cytometry, and flow cytometry. Mononuclear cells can also be derived from stem cells, such as induced pluripotent stem cells, embryonic stem cells, and somatic stem cells.In particular embodiments, peripheral blood mononuclear cells (PBMCs) can be used as mononuclear cells in the present disclosure. PBMCs can be isolated by density gradient centrifugation using commonly used density gradient medium such as Ficoll or Ficoll-Paque. The density gradient medium can also include sodium diatrizoate, polysaccharides, and water. The PBMCs can be cryopreserved before being used in the methods of the present disclosure. Cryopreservation of PBMCs can include resuspension of the PBMCs in a freezing medium. In particular embodiments, the freezing medium is 10-20% dimethyl sulfoxide (DMSO) and 40% fetal bovine serum (FBS) or human serum albumin (BSA) in RPMI-1640 medium. In particular, the PBMCs in freezing medium can be placed in a freezer at -80°C overnight to allow for gradual and uniform cooling.The frozen cells can be transferred to a liquid nitrogen tank the following day for long-term storage.
[0006] Cryopreserved PBMCs can be thawed for use in the methods of this disclosure. Specifically, thawing PBMCs includes removal from liquid nitrogen and placement on ice, followed by thawing in a 37°C warm water bath. Thawing may further include adding warm medium supplemented with 10% FBS, 1% penicillin / streptomycin, and L-glutamine; washing the cells to remove DMSO; and resuspending the cells in medium. Thawing may also include allowing the PBMCs to rest overnight to eliminate apoptotic cells. After this resting period, the cells are washed and then ready for use in culture. Cryopreserved PBMCs were thawed and untreated in RPMI 1640 (supplemented as described above) or stimulated with cytokines, stimulated via the T-cell receptor (TCR), or stimulated by a combination of both treatments.Cytokine stimulation was performed with IL-12 (Invitrogen, Carlsbad, California), IL-15 (Invitrogen, Carlsbad, California), and IL-18 (MBLI, Woburn, Massachusetts) at 100 ng / ml. TCR stimulation was performed with Dynabead Human T-Cell Activator (Invitrogen, Carlsbad, California) anti-CD3 / CD28 beads at a 1:1 bead / T-cell ratio. Whole PBMCs were either unstimulated or stimulated at a concentration of 1.25 × 10⁶ per well using a 96-well plate for 6 and 24 hours at 37°C to enable CTLA-4 expression. MAIT cells stimulated for only 6 hours required at least 12 hours of rest in culture for sufficient CTLA-4 induction. Cytokines and TCR beads were removed by magnetic extraction and washing. In short, Dynabeads were removed using EasySep™ Magnet (STEMCELL Technologies Inc., Cambridge, Mass.).The cells were transferred into 5 ml round polystyrene tubes, and 0.5 ml of 1×PBS (phosphate-buffered saline) was added to each tube. Each tube was placed in an EasySep Magnet™ for 1 min. To hold the tube in place within the magnet, the entire contents of the first tube were poured into another tube outside the magnet. The magnetic Dynabeads remained in the first tube inside the EasySep Magnet™ while cells were transferred to the new tube. The cells were washed twice by centrifugation at 2000 rpm for 3 min and resuspension in 200 µL of RPMI 1640 (supplemented as described above). After washing, the cells were resuspended in 200 µL of RPMI 1640 (supplemented as described above) before being transferred back to a 96-well plate for culture. To block TCR signaling, cells in the cytokine-only state were treated with an anti-MR1 antibody (clone 26.5, Biolegend, San Diego, California) at 50 µg / ml.The cells were then stained with antibodies for flow cytometric detection and analysis as described above.
[0007] WO 2014 069 072 A1 discloses a preparation method for a MAIT-like cell, consisting of introducing a reprogramming factor into a MAIT cell to obtain an induced pluripotent stem cell that retains a TCR-α chain gene rearranged in a MAIT cell-specific fashion. Differentiation of the induced pluripotent stem cell is then induced to obtain a MAIT-like cell. The preparation method for an induced pluripotent stem cell consists of introducing a reprogramming factor into a MAIT cell to obtain an induced pluripotent stem cell that retains a TCR-α chain gene rearranged in a MAIT cell-specific manner. MAIT cells within the scope of the present invention are T cells whose TCR-α chain gene is rearranged to form a unique and uniform Vα-Jα (Vα19-Jα33 in a mouse, Vα7.2-Jα33 in humans).They can particularly preferably be defined as cells expressing CD161 or IL-18Rα. Furthermore, the MAIT cell can be characterized by its TCR-α chain being restricted by the invariant MR1. The MAIT cell in the present invention can also be identified by the expression of genes specific to the MAIT cell or by a cell biological characteristic specific to the MAIT cell. Any cultivation method for obtaining MAIT-like cells by inducing differentiation in the present invention can be used, provided that MAIT-like cells can be obtained, and examples include co-culture with feeder cells, float culture, hanging-drop culture, rotary culture, soft agar culture, and microcarrier culture.In a preferred aspect of the present invention, it is preferred to obtain MAIT-like cells by inducing the differentiation of iPS cells through co-culture. In particular, MAIT-like cells can be efficiently obtained from MAIT-iPS cells by co-culture using stromal cells, such as OP9 cells, as feeder cells, followed by co-culture with OP9 cells that strongly express a Notch ligand DLL1 (OP9 / DLL1), or by co-culture performed from the outset with the OP9 / DLL1 cells. The MAIT-like cells obtained by such a method can subsequently be subjected to cell collection, separation, and purification using known methods. The MAIT-like cells obtained by the present invention are cells with morphological, physiological, and / or immunological characteristics that are nearly equivalent to those of a living MAIT cell.
[0008] In invention WO 2021 0856 450 A1, a culture method for obtaining m-reMAIT-like cells by inducing differentiation is described, whereby the method is not limited to co-culture methods with feeder cells, suspension culture methods, hanging drop culture methods, fluidized bed culture methods, soft agar culture methods, microcarrier culture methods, and the like. In a preferred embodiment of the present invention, co-culture is particularly suitable for inducing the differentiation of iPS cells to obtain m-reMAIT cells. In particular, stromal cells such as OP9 cells are used as feeder cells and further co-cultured. This can be achieved by co-cultivation with OP9 cells (OP9 / dlk-1) through forced expression of the Notch ligand Delta-like 1 (dlk-1) or by co-culturing with OP9 / dlk-1 cells from the outset. M-reMAIT cells can be efficiently obtained from MAIT iPS cells.
[0009] WO 2021 122 961 A1 discloses a method for the proliferation, expansion, activation, and / or survival of MAIT cells. In some embodiments, the MAIT cells are incubated under stimulating conditions or in the presence of a stimulating agent. These conditions include those designed to induce the proliferation, expansion, activation, and / or survival of MAIT cells and / or to mimic antigen exposure. The conditions may include one or more specific media, temperature, oxygen content, carbon dioxide content, time, active substances (e.g., nutrients, amino acids, antibiotics, ions), and / or stimulating factors such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other active substances for activating the MAIT cells.For example, MAIT cells can be incubated with an anti-CD3 antibody and / or an anti-CD28 antibody under conditions that stimulate cell proliferation. In some embodiments, the MAIT cells according to the invention can be expanded in vitro by co-cultivation with tissue or cells. In some embodiments, the MAIT cells are expanded by co-cultivation with feeder cells, such as non-dividing PBMC. In some aspects, the non-dividing feeder cells can include irradiated PBMC feeder cells, in particular autologous or allogeneic irradiated PBMC, or other cells expressing MR1. In some embodiments, MAIT cells are expanded in vitro by CD3 / CD28 stimulation in the presence of autologous or allogeneic irradiated PBMCs and IL-2, IL-7, IL-12, IL-18, and / or IL-15 cytokines.In further embodiments, MAIT cells are expanded and / or activated in vitro in the presence of MAIT cell-activating ligands such as 5-OP-RU and / or 5-OE-RU. In some embodiments, the method includes a preferred in vitro MAIT cell expansion step from a donor cell sample, particularly from donor PBMCs. A preferred in vitro MAIT cell expansion can be carried out by culturing donor PBMCs in the presence of synthetic 5-OP-RU and optionally with cytokines. In particular, donor PBMCs are cultured in the presence of 5-OP-RU and IL-2 (such as rhulL-2). In some embodiments, the MAIT cells are preferably expanded ex vivo for at least about 5 days, preferably not less than about 10 days, particularly preferably not less than about 15 days, and most preferably not less than about 20 days prior to administration to the patient.In some embodiments, the MAIT cells have been expanded at least 100-fold, preferably at least 200-fold, and particularly preferably at least 400-fold, preferably at least 600-fold, particularly preferably at least 1000-fold, and even more preferably at least 1500-fold compared to day 0 of expansion prior to administration to a patient. In some embodiments, the manufacturing process includes steps for freezing, e.g., cryopreservation, the cells, either before or after isolation, incubation, and / or processing.
[0010] WO 2020 127 513 A1 describes a mucosa-associated invariant T cell (MAIT) expressing a chimeric antigen receptor (CAR) for use in the treatment of cancer, an immune disorder, or an infectious disease in a volunteer, wherein the MAIT cell is allogeneic with respect to the volunteer. In one aspect, the CAR-MAIT cell is to be administered to an immunocompromised volunteer. Specifically, the CAR-MAIT cell is to be administered following a conditioning treatment that induces immunosuppression in the volunteer. The conditioning treatment may consist of chemotherapy, radiotherapy, and / or lymphodecentrating antibodies. Preferably, the MAIT cell expresses a CAR that specifically binds to a tumor-associated antigen (TAA). The TAA may be expressed on the surface of tumor cells.Preferably, the TAAs are CD19, GD2, EGFR, CD20, CD22, CD33, CD138, CD52, CD30, ROR1, HER2, EpCAM, MUC-1, MUC5AC, BCMA, CD38, SLAMF7 / CS1, CD123, IL-13Ra2, HER2, LeY, MUC16, or PSMA. Particularly preferred are the TAAs CD19, CD20, CD22, CD33, CD138, BCMA, CD38, SLAMF7 / CS1, IL-13Ra2, or HER2. The present invention provides mucosa-associated invariant T (MAIT) cells expressing a chimeric antigen receptor (CAR), hereinafter referred to as CAR-MAIT cells, for use in the field of allogeneic adoptive immunotherapy. The CAR-MAIT cells do not exhibit alloreactive potential. They do not proliferate in vitro in response to allogeneic cells and, unlike conventional T cells, do not participate in the induction of graft-versus-host disease (GvHD). According to the invention, CAR-MAIT cells can be easily produced and expanded in vitro in large quantities. CAR-MAIT cells can, for example, be used to induce graft-versus-host disease (GvHD).They are stored in deep-freeze units and are ready-to-use to allow for timely administration to multiple recipients. Their preparation is cost-effective and represents a universal treatment, regardless of HLA disparity between subjects and without the risk of inducing GVHD. The cells can be obtained from blood samples (including peripheral blood and umbilical cord blood) as well as from samples resulting from one or more processing steps such as separation, centrifugation, genetic engineering, washing, and / or incubation. In one embodiment, the donor sample includes peripheral blood mononuclear cells (PBMCs). In another embodiment, MAIT cells are collected from any location within the subject, including but not limited to peripheral blood, peripheral blood mononuclear cells (PBMCs), bone marrow, and umbilical cord blood.In one particular embodiment, the MAIT cells are collected by apheresis, specifically leukapheresis. As is known to those skilled in the art, various methods for isolating immune cells from a subject are available or can be adapted to the current application, for example, using the Life Technologies Dynabeads System®; STEMcell Technologies EasySep, RoboSep™, RosetteSep™, SepMate™; Miltenyi Biotec MACS cell separation kits™, cell surface marker expression, and other commercially available cell separation and isolation kits (e.g., ISOCELL from Pierce, Rockford, IL). MAIT cells can be isolated using beads or other binding agents available in such kits that are specific for MAIT cell surface markers. For example, MAIT cells can be incubated with an anti-CD3 antibody and / or an anti-CD28 antibody under conditions that stimulate cell proliferation.In one particular embodiment, MAIT cells are expanded and / or activated in vitro in the presence of MAIT cell-activating ligands such as 5-OP-RU and / or 5-OE-RU. In another particular embodiment, the method comprises a preferred in vitro MAIT cell expansion step from a donor cell sample, in particular from donor PBMCs. A preferred in vitro MAIT cell expansion can be carried out by culturing donor PBMCs in the presence of synthetic 5-OP-RU and optionally with cytokines. In particular, donor PBMCs are cultured in the presence of 5-OP-RU and IL-2 (such as rhuIL-2). In a particular embodiment, the MAIT cells are preferably expanded ex vivo for at least about 5 days, preferably not less than about 10 days, particularly preferably not less than about 15 days, and most preferably not less than about 20 days prior to administration to the patient.In a further embodiment, the MAIT cells have been expanded at least 100-fold, preferably at least 200-fold, and particularly preferably at least 400-fold, preferably at least 600-fold, particularly preferably at least 1000-fold, and even more preferably at least 1500-fold compared to day 0 of the expansion prior to administration to a patient.
[0011] EP 09 10 624 B1 describes a method for multiplying lymphocytes in a cell culture, in which lymphocytes are cultured and multiplied in a cell culture medium containing a lymphocyte growth factor as well as aurinitricarboxylic acid or a substance that binds to a cyclophilin and inhibits calcineurin in this complex. The cell culture medium contains cyclosporine, ascomycin, and / or tacrolimus as the cyclophilin-binding substance. Lymphocytes are leukocytes found in the blood, lymph, spleen, lymph nodes, tumors, or inflamed tissues and are classified as T lymphocytes, B lymphocytes, or NK cells. Lymphocyte growth factors are selected from T-lymphocyte, B-lymphocyte or NK-lymphocyte growth factors, preferably from the group IL-2, IL-10, IL-13, IL-14 and IL-15.A lymphocyte growth factor is a substance capable of promoting lymphocyte cell division. Lymphocyte growth factors are widely known to experts. Suitable T-lymphocyte growth factors include, for example, interleukin-2 (IL-2) and interleukin-15 (IL-15). A suitable NK-lymphocyte growth factor is, for example, IL-15. Suitable B-lymphocyte growth factors include, for example, interleukin-13 (IL-13), IL-14, and IL-10 (Callard, RE, and Gearing, JH, The Cytokine Facts Book, Academic Press, London, 1994). Tumor-infiltrating lymphocytes are cultured and after ten days of culture a mixture of T lymphocytes (CD3+, CD4+, CD8+, CD19-), NK cells (CD2+, CD3-, CD56+, CD19-) and B lymphocytes (CD19+, CD3-) can be detected.
[0012] Tumor-infiltrating lymphocytes proliferate in a medium containing interleukin-2 (IL-2) and aurinitricarboxylic acid (ATA), in the context of a human colon carcinoma nodule surgically removed from the colon, surrounded by connective tissue and The tumor fragments are removed from normal intestinal segments and cut into pieces approximately 2 × 2 × 3 mm in size. They are then mounted in Iscove-modified DME medium (Gibco) containing 15% FBS (BM) and evenly distributed among four culture dishes.
[0013] German patent DE 10 2021 002 748 A1 discloses a method for isolating, activating, and multiplying immune cells, in particular tumor-infiltrated autologous T lymphocytes (TILs) from primary tumor tissue, metastases, lymphatic tissue, but also T cells from other tissues (e.g., blood, lymph fluid) in a meander perfusion bioreactor, and for producing immune cell therapeutics from these for combating tumors of the pancreas, lung, liver, prostate, breast, ovary, stomach, colon, rectum, bone, brain, skin, and other malignant tumors. • the flow conditions in the channel of a perfusion bioreactor, • the formation of a largely static cell layer in which the cells touch, but slight movements can also occur, with TIL cell numbers in the sedimented layer being between 0.1 and 2 × 106 TIL / cm2, preferably between 0.5 and 1 × 106 TIL / cm for continuous proliferation, • the culture medium contains cytokines and antibodies, wherein the cytokines are in the form of interleukin 12 or a mixture of interleukin 2 and interleukin 12, and the antibodies are in the form of antibody 4-1bb and • the hyperoxic or normoxic supply of the cells with supplemented medium and oxygen depending on the increased number of TILs or other T cells.
[0014] EP 3 601 533 B1 describes an improved and / or shortened method for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system. This results in improved efficacy, phenotype, and metabolic health of the TILs in a shorter timeframe, while simultaneously reducing microbial contamination and lowering costs. Such TILs are used in therapeutic treatment regimens. The method consists of: (a) Obtaining an initial population of TILs from a tumor resected from a patient (b) Adding the tumor fragments to a closed system; (c) Performing a first expansion by cultivating the first population of TILs in a cell culture medium containing IL-2 to produce a second population of TILs, wherein the first expansion is carried out in a closed container providing a first gas-permeable surface, wherein the first expansion is carried out for about 3 to 14 days to obtain the second population of TILs, wherein the second population of TILs is at least 50 times larger than the first population of TILs, and wherein the transition from step (b) to step (c) is made without opening the system; (d) Performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3 and antigen-presenting cells (APCs) to generate a third population of TILs, wherein the second expansion is carried out for approximately 7 to 14 days to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs, wherein the second expansion is carried out in a closed container providing a second gas-permeable surface, and wherein the transition from step (c) to step (d) is made without opening the system; (e) Extraction of the therapeutic population of TILs obtained from step (d), the transition from step (d) to step (e) taking place without opening the system; and (f) Transfer of the harvested TIL population from step e) into an infusion bag, the transition from step (e) to (f) taking place without opening the system.
[0015] The methods described in the prior art for expanding cells, particularly non-adherent T lymphocytes or NK cells, but also other immune cells such as tumor-infiltrated NK cells (TINK), are performed in culture dishes or 24- or 96-well plates. A high proportion of pooled human antibiotic serum (5% to 10%) is added to the culture medium, which represents a significant cost factor in T-lymphocyte expansion and may result in insufficient quantities of T lymphocytes being available for therapeutic treatment. Furthermore, after cultivation, a mixture of T lymphocytes (CD3+, CD4+, CD8+), NK cells (CD2+, CD56+), and B lymphocytes (CD19+) is detectable, but a high proportion of T lymphocytes containing a mixture of CD8+ and CD56+ antibodies has not been expanded.
[0016] The object of the invention is to develop a method for expanding cells, in particular non-adherent cells such as invariant T lymphocytes or non-adherent T lymphocytes and NK cells, but also other immune cells, e.g., tumor-infiltrated NK cells (TINK) and mucosa-associated invariant T cells (MAIT) with a high proportion of CD8+ and CD56+ antibodies, or with a low proportion of CD3+ antibodies, in which sufficient quantities of cells are made available for therapeutic cell treatment and the high costs, in particular those arising from the use of human sera in the expansion, are avoided.
[0017] The task is solved by a method for expanding cells, especially non-adherent cells such as invariant T lymphocytes or non-adherent T lymphocytes and NK cells, but also other immune cells, e.g., tumor-infiltrated NK cells (TINK) and mucosa-associated invariant T cells (MAIT) with a high proportion of CD8 and CD56 antibodies, and also with a low proportion of CD3+ antibodies, in a perfusion plate meander bioreactor, wherein the culture medium guided in cofferdam 10 is overlaid by overlay media, the perfusion plate meander bioreactor consisting of several superimposed and rotated 180° relative to each other,consisting of channels 10 formed by ribs 13 and overflows 14 arranged in the cultivation carriers as well as overflow ribs 33 arranged in the direction of flow in front of the overflows 14 and wherein the culture medium in a bioreactor vessel 1 is guided horizontally in the channels 10 on the cultivation carriers 7 of the bioreactor vessel 1 and meanders vertically from cultivation plate 7 to cultivation plate 7 up to the outflow 23 for the culture medium in the cultivation carriers 7 below the cultivation carrier 7 via the overflows 14 and over the overflow rib 33. The overlay media are guided in channels 10 from the feeding overlay cavity 12 towards the overflows 14 and meandering from bottom to top to the outlet 22 for overlay media, for gas diffusion of the overlay media into the culture medium and for maintaining a constant concentration of the dissolved overlay media in the culture medium above the surface of the culture medium.
[0018] Fragmented tissue fragments, particularly finely chopped tissue pieces derived from surgical specimens or biopsies, are introduced into the culture medium and, in a first stage, cells grow in a perfusion meander bioreactor suitable for cell growth. Once a certain density of mature and expanded cells is reached, these are separated from the tissue fragments and supplemented in the culture medium. This culture medium consists of standard base media with a mixture of AB human serum, antibodies, cytokines, lymphocyte growth factors, and human feeder cells. Glycol is transferred to a perfusion plate meander bioreactor, expanded, activated, and harvested. AB human serum is added to the culture medium at a concentration of 2% of the total volume, along with membrane components from lysed human autologous feeder cells.
[0019] Furthermore, coated particles as indicator beads with a size of 10–100 µm, in particular hollow ceramic spheres made of polystyrene or spray granules, coated with a fluorescent marker, especially indocyanine green, are added to the culture medium and illuminated by a suitable light source 18 with a wavelength between 750 nm and 950 nm, in particular with a light source with a wavelength of 830 nm in the fluorescence spectrum for blood, whereby the fluorescence brightness of the fluorescent marker changes with the change in the concentration of overlay media, in particular O2. The lower the concentration of overlay media, in particular O2, in the culture medium, the greater the fluorescence brightness.
[0020] The density of the culture medium is 1.077 g / cm³. 3 The density of the hollow ceramic spheres with air inclusion is 1.09 to 1.1 g / cm³. 3and is only slightly higher than that of the culture medium. Therefore, the spheres are expected to settle in the flowing medium over longer periods of time. The pulse generator 31, attached to the vibrating table 30, causes the culture medium in the channel 10 to be agitated vertically to the flow direction by jerks of 2-5 m / s at defined time intervals, in particular 1 to 3 times per day. 3 The process accelerates abruptly, resulting in a mixing of the media components and the indicator spheres.
[0021] As the number of cells increases during the cultivation process, so does the glucose requirement and the oxygen requirement in the overlay.
[0022] By measuring and evaluating the brightness gradient of the light-emitting indicator spheres during inflow and outflow, the cell proliferation rate can be increased by changing the flow rate of the culture medium and overlay media according to predefined algorithms. This leads to time savings and cost reductions in the culture medium used for cell cultivation.
[0023] As described above, glucose is supplied via the culture medium depending on the O2 concentration in the culture medium, whereby the concentration of O2 is determined and regulated by the fluorescence brightness of the fluorescent marker.
[0024] The width of the channels 10 is chosen and the amount of culture medium supplied and discharged is adjusted such that a laminar flow with a bed-to-bed particle count of 0.001 to 0.1 develops in the streams within the channels 10, while the bed-to-bed flow remains close to a bed-to-bed particle count of 0. The distance b of the channels from the end walls is chosen such that the culture medium can flow out through the overflows 14 and over the overflow bridges 33 without flow losses.
[0025] The Bodenstein number is a dimensionless parameter that describes the ratio of moles supplied convectively to those supplied by diffusion. Thus, the Bodenstein number characterizes the backmixing within a system (the larger the Bodenstein number, the lower the backmixing) and allows conclusions to be drawn about whether and to what extent volume elements or substances mix within the channels 10 due to the prevailing currents. Backmixing is greatest when the Bodenstein number is 0 or close to 0; that is, when the Bodenstein number is close to 0, the overlay media are optimally mixed with the culture medium, and the cells are thus optimally supplied with the overlay media during their expansion. The Bodenstein number Bo is defined as Bo = u × L / D ax , where u is the flow velocity, L is the length of the reactor, here the length of the channels 10 and D axThe dispersion coefficient is represented. Since the length of the channels 10 is given and the Bodenstein number Bo=0 represents ideal backmixing, the dispersion coefficient, and thus the distribution of the overlay media, in particular the distribution of O2, depends on the flow velocity of the culture medium and the length of the reactor, which can then be recognized and controlled by the fluorescence brightness in the channels 10 according to the overlay media distribution in the culture medium.
[0026] The overlay media flow over the culture medium into the channels 10 arranged on the culture carrier 7 with a laminar flow characterized by Froud's number 0 < Fr <1.
[0027] The Froude number describes the ratio of flow velocity to the propagation speed of a shallow water wave, whereby in a flowing flow state the wave propagation shows a parabolic pattern.
[0028] The culture medium in the perfusion plate meander bioreactor is guided in a meandering pattern from top to bottom via the culture carriers 7 with coagulations 10 and overflows 14, and the overlay media are guided alternately in the same and opposite direction to the flow of the culture medium, whereby the cells are supplied with O2 normoxemicly and also hyperoxemicly with an O2 concentration of 23 - 25% via the overlay media during the expansion.
[0029] The proportion of expanded cells that are coated with the antibodies CD 8+ and CD 56+ is 70 to 80% when expanded using this method, with the antibody CD3+ also docked to the cells in small quantities.
[0030] Lymphocyte growth factors used include interleukin 12 alone, a mixture of interleukin 2 and interleukin 12, or a mixture of IL12, IL15 with the addition of antibody 4-1 BB.
[0031] In one embodiment of the invention, the plate plane of the cultivation carrier 7 of the perfusion plate meander bioreactor arranged on a vibrating plate 30 with a pulse generator 31 is arranged horizontally and mechanically vibrated in the direction of gravity at time intervals, in particular 1 to 3 times / day, wherein the applied jerk is between 2-5 m / s 3 amounts.
[0032] The plate surface of the cultivation carrier 7 can also be vibrated electromechanically.
[0033] This reduces the segregation of TIL cells due to sedimentation during flow in the clots, increases the proliferation rate, and shortens the transit time for planned cell proliferation. This leads to an earlier start to treatment, resulting in higher cure rates and lower costs.
[0034] In a further embodiment of the invention, the cells in the culture media can be subjected to shear stress during expansion, wherein a portion of the culture medium is guided through a bypass 26 outside the perfusion plate meander bioreactor through a constriction of the bypass 26 created with an electromagnetic hose clamp 27.
[0035] The invention is explained in more detail using an example, wherein the Fig. 1. A flow diagram of the perfusion plate meander bioreactor, which Fig. 2 a schematic side view, which Fig. 4. A 3D top view of the bioreactor, which Fig. 5 a representation of the cultivation carrier 7 and the Fig. 3 a schematic side view with the bypass 26 of the perfusion plate meander bioreactor with vibrating table 30 and pulse generator 31, where 1 bioreactor vessel 2 floors 3 lids 4 Front wall 5 Front wall 6 side wall 7 Cultivation carriers 8 clamping brackets 9 clamping nut 10 channels 11 Feed cavity 12 feeds for overlay media 13 bridges 14 Overflow 15 Collection chamber 16 Space for overlay media 17 feet 18 Light source 19 skylights 20 Luer-lock connectors for feeding overlay media 21 Luer-lock connectors for supplying cultural media 22 Luer-lock connectors for the discharge of overlay media 23 Luer-lock connectors for the removal of cultural medium 24 Overlay Cavity 25 cultural media 26 Bypass 27 electromagnetic hose clamp 28 Three-way chick rooster 29 Luer-Lock connectors 30 vibrating table 31 pulse generators 32 camera 33 overflow bridges mean.
[0036] A culture medium consists of a cell growth medium that is temporarily supplemented with a specific mixture of AB human serum, cytokines, antibodies, and irradiated human feeder cells. Autologous tumor tissue fragments, measuring 1 to 2 mm, harvested from the patient during surgery and fragmented, are then added to this culture medium. 3Polystyrene particles coated with indocyanine green, measuring 10–100 µm, are added and fed to the bioreactor vessel 1 via the Luer-lock connector 21 for culture medium supply. The culture medium is supplemented only with AB human serum at a concentration of 2% of the total volume and with membrane components from lysed human autologous feeder cells, the membrane components of which are added 4–5 days after the start of expansion. The fragmented tissue pieces are evenly distributed in the bioreactor and cultured under perfusion. The culture medium is supplied with the appropriate overlay atmosphere via the overlay media supplied through the supply cavity 11 and the inlets 12 for overlay media into the overlay chambers 16. During a cultivation run of 7 to 14 days, cells (TIL or other cells) grow in sufficient quantity.As the cell number increases, the supply of fresh medium is continuously increased during the multiplication of the cell quantity (TIL or other cells), with the increased supply of fresh medium being automatically controlled by a corresponding algorithm.
[0037] The perfusion plate meander bioreactor consists of a polystyrene bioreactor vessel 1, which comprises a base 2, a lid 3, end walls 4, 5, and side walls 6. Several, in particular eight, culture carriers 7 are attached to the bioreactor vessel 1 at a distance of 11.5 mm via clamping nuts 9 and a clamping bracket 8. Channels 10 are formed on the culture carriers 7 by means of ribs 13, through which the culture medium and gaseous overlay media are guided. The culture medium is discharged via an overflow rib 33, 6 mm high, and through one or more overflows 14 onto the culture carrier 7 below.This underlying culture carrier 7, with its overflows 14 and overflow bridge 33, is mounted rotated 180° relative to the culture carrier 7 above it, so that the culture medium flows meanderingly from top to bottom into the culture medium collection chamber 15 and is discharged from the bioreactor vessel 1 via the Luer-lock connector 23. The distance a between the bridges 13 is chosen and the amount of culture medium supplied and discharged is adjusted such that a laminar flow with a plate count of 0.001 to 0.1 develops in the stream, in the channel 10 formed by the bridges 13, for optimal supply of the expanding cells, and the bottom flow remains close to a plate count of 0.This is achieved primarily by the overflow bridge 33 with a height of up to 6 mm, because the flow velocity (u) in the laminar boundary layer at the bottom of the channel 10 is close to 0 and thus the number of bed stones Bo is approximately 0) (u is proportional to Bo).
[0038] A feed cavity 11 for overlay media is incorporated into the end wall 4. This cavity is connected via feeds 12 for overlay media to overlay chambers 16 located above the culture carriers 7 containing the flowing culture medium. The overlay media is conveyed countercurrently over the culture medium via the Luer-lock connector 20, which is connected to the feed cavity 11 for overlay media, into the collection chamber 24 for overlay media. From there, the overlay media is discharged from the bioreactor vessel 1 via the Luer-lock connector 22.
[0039] The bottom 2 of the bioreactor vessel 1 has a light window 19, beneath which a light source 20 with a wavelength of 830 nm in the blood fluorescence spectrum is mounted, equipped with a video camera 32. This camera is used to monitor and control the backmixing of the overlay media into the culture medium. The culture medium is coated with indocyanine green polystyrene particles to detect backmixing. Changes in the color of these particles indicate changes in the concentration of overlay media, particularly the concentration of O2. The lower the concentration of overlay media, especially O2, in the culture medium, the greater the fluorescence brightness.
[0040] Instead of the Luer-Lock connector 20, a three-way chick stopcock 28 can be arranged in the end wall 4 and a Luer-Lock connector 29 connected to the space for the culture medium 25 of this culture carrier 7 can be arranged in the end wall 5 above the centrally arranged culture carrier 7, wherein the three-way chick stopcock 28 and the Luer-Lock connector 29 are connected to each other via a bypass 26 and wherein an electromagnetic hose clamp 27 is arranged in the bypass 26.
[0041] By switching the three-way chick stopcock 28 and the Luer lock connector 29, a portion of the culture medium can be directed through the bypass 26. The narrowing of the cross-section of the bypass 26 allows a definable shear stress to be exerted on the expanding cells in the culture medium. Cell activation, particularly of T cells, is both a mechanical and a biochemical process. The electromagnetic tube clamp 27 applies a reproducible, defined shear stress to the cells, especially T cells, thus mechanically stimulating their activation.
[0042] The bioreactor vessel 1 is arranged on a vibrating table 30 with a pulse generator 31, wherein a light source 18 with a wavelength in the fluorescence spectrum for blood of 830 nm, with a camera 32, is attached to the bottom 2 of the bioreactor vessel 1 under a polished light window 19.
[0043] The glucose supply via the culture medium is controlled depending on the O2 concentration in the culture media, whereby the concentration of O2 is determined by the fluorescence brightness of the fluorescent marker and the glucose supply is regulated accordingly.
[0044] The culture medium, which flows through 10 parallel, hydraulically separated channels 10 on the cultivation platform 7, and at the end of the cultivation platform 7 flows through the overflows 14 onto the cultivation platform 7 below, and then flows back through the channels 10 in the opposite direction, has a very low flow velocity of approximately 1 cm / min and thus meanders vertically. Based on the entire channel area, this results in a Reynolds number between 10 <Re<50 <<2320 =Rekrit., was bei der geringen Strömungsgeschwindigkeit zu einer gesichert laminaren Strömung bei einer Bodensteinzahl Bo nahe null führt.
[0045] The Bodenstein number Bo is defined as Bo= u × L / Dax, where u is the flow velocity, L is the length of the reactor, here the length of the channels 10 and D ax The dispersion coefficient is represented. Since the length of the channels 10 is given and the Bodenstein number Bo=0 represents ideal backmixing, the dispersion coefficient and thus the distribution of the overlay media, in particular the distribution of O2, depends on the flow velocity of the culture medium, which can then be recognized and controlled by the fluorescence brightness in the channels 10, corresponding to the distribution of the overlay media in the culture medium.
[0046] The overlay media flow above the culture medium into the channel 10 arranged on the culture carrier with a laminar flow characterized by Froud's number close to 0.
[0047] The culture medium in the perfusion plate meander bioreactor is guided in a meandering pattern from top to bottom via the culture carriers 7 with the channels 10 and overflows 14, and the overlay media overflow from bottom to top in the opposite direction to the flow of the culture medium, whereby the cells are supplied with O2 via the overlay media during expansion in a normoxemic or hyperoxemic manner with an O2 concentration of 23 - 25%.
[0048] The proportion of expanded cells that are coated with the antibodies CD 8+ and CD 56+ is 70 to 80% when expanded using this method, with the antibody CD3+ also docked to the cells in small quantities.
[0049] Lymphocyte growth factors used include interleukin 12 alone, a mixture of interleukin 2 and interleukin 12, or a mixture of IL12, IL15 with the addition of antibody 4-1 BB.
[0050] The plate plane of the cultivation carrier 7 of the perfusion plate meander bioreactor arranged on a vibrating plate 30 with a pulse generator 31 is horizontally arranged and is mechanically jerked in the direction of gravity at time intervals, in particular 1 to 3 times / day, whereby the applied jerk is between 2-5 m / s 3 amounts.
[0051] The plate surface of the cultivation carrier 7 can also be vibrated electromechanically.
[0052] The cells in the culture medium will be subjected to shear stress during expansion, with part of the culture medium being guided through a bypass 26 outside the perfusion plate meander bioreactor through a constriction of the bypass 26 created by an electromagnetic hose clamp 27.
Claims
[1] Method for the expansion of cells, such as non-adherently growing cells, invariant T lymphocytes, non-adherently growing T lymphocytes, NK cells, tumor-infiltrated NK cells (TINK), mucosa-associated invariant T cells (MAIT) or other immune cells with a high proportion of CD8+ and CD56+ antibodies and with a low proportion of CD3+ antibodies in a perfusion plate meander bioreactor with countercurrent culture medium and overlay media streams, whereby cells grow from crushed tissue pieces obtained from surgical tissue or biopsies in a closed perfusion meander process in a first stage and, after reaching a certain density of fully grown and expanded cells, are separated from the tissue pieces, supplemented in suitable culture medium and placed in a culture carrier (7) consisting of several vertically stacked and mutually rotated by 180°,Perfusion plate meander bioreactor, are introduced, expanded, activated and harvested, whereby on the cultivation carrier (7) channels (10), overflows (14) and overflow webs (33) are arranged and the culture medium consists of usual base medium with a mixture of AB human serum, antibodies, cytokines,Lymphocyte growth factors and human feeder cells with supplemented glycol as well as in the bioreactor vessel (1) in the channels (10) on the culture supports (7) of the bioreactor vessel (1) horizontally and through the overflows (14) into the culture support (7) and over the overflow webs (33) meandering vertically from culture plate (7) to culture plate (7) to the outlet (23) for the culture medium and the overlay media overflow is guided counter to the flow of the culture medium in the channels (10) for gas diffusion of the overlay media into the culture medium and for maintaining the concentration of the dissolved overlay media in the culture medium above the surface of the culture medium in the channels (10), characterized by , that • the culture medium is supplemented with AB human serum in an amount of 2% of the total amount and with membrane fractions from lysed human, autologous feeder cells and • Indicator beads in a size of 10 - 100 µm, which are coated with fluorescent marker, are added to the culture medium and illuminated by a light source with a wavelength of between 750 nm and 950 nm, whereby the fluorescence brightness of the fluorescent marker changes due to the change in the O2 concentration in the overlay media [2] Method according to claim 1, characterized by that the cells are supplied with normoxemic O2 or hyperoxemic O2 concentration of 23 - 25% via the overlay media during expansion. [3] Method according to claim 1, characterized by that the indicator beads are made of polystyrene or hollow ceramic beads made of spray granules. [4] Method according to claim 3, characterized by that the coated indicator beads, which consist of hollow ceramic spheres made from spray granules, consist of mixtures of ZrO2 and Al2O3. [5] Method according to claim 1 and 2, that the culture medium, which is guided in parallel, hydraulically separated, channels (10) on the cultivation support (7) through the channels (10) and flows at the end of the cultivation plate (7) through the overflows (14) onto the underlying cultivation plate (7) and then in the opposite direction through the channels (10), has a flow velocity of 1 cm / min and meanders vertically, wherein, based on the entire channel area, a Reynolds number of between 10 <Re<50 <<2320 =Re krit . and a laminar flow is established at a Bodenstein number Bo close to zero. [6] Method according to claims 1-4, characterized by that the fluorescent marker consists of indocyanine green. [7] Method according to claim 1, characterized by that the culture medium with the added particles is irradiated with a light source with a wavelength in the fluorescence spectrum for blood of 830 nm. [8] Method according to claims 1-7, characterized by that the proportion of cells with CD 8+ and CD 56+ antibodies is 70 to 80%. [9] Method according to claims 1-8, characterized by that the lymphocyte growth factors consist of interleukin 12 alone or of a mixture of interleukin 2 and interleukin 12 or of a mixture of IL12, IL15 and all mixtures additionally contain the antibody 4-1 BB. [10] Method according to claims 1-9, characterized by that the membrane components from lysed human, autologous feeder cells are added to the culture medium 4 - 5 days after the start of cell expansion. [11] Method according to claims 1-10, characterized by that the control of the glucose supply via the culture medium is dependent on the O2 concentration in the culture medium, whereby the concentration of O2 is determined and regulated by the fluorescence brightness of the fluorescent marker. [12] Method according to claim 1 - 11, characterized bythat in the culture medium during the meandering flow through the perfusion meander plate bioreactor, jerky liquid swirls are generated by one or more jerks from the outside on the perfusion plate meander bioreactor in the culture medium flowing through the channels (10) of the cultivation carriers (7). [13] Method according to claims 1-12, characterized by that the plate plane of the cultivation carriers (7) are arranged horizontally on a perfusion plate meander bioreactor arranged on a (not shown) shaking device and are mechanically shaken in the direction of gravity at time intervals, the introduced jerk impulse being between 2-5 m / s 3 amounts. [14] Method according to claims 1-13, characterized by that the jerk pulse is introduced into the culture medium at a time interval of 1 to 3 times / d. [15] Method according to claims 1-14, characterized bythat the plate plane of the cultivation carriers (7) is jerked electromechanically. [16] Method according to claims 1-15, characterized by that the culture medium is subjected to a defined shear stress via a Luer Lock connector (29) and a three-way plug valve (28) via a bypass (26) by an electromagnetic hose clamp (27).
Citation Information
Patent Citations
Process for producing and multiplying lymphocytes
EP0910624B1
Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
EP3838288A1
Systems and methods for immunomodulation of mucosal-associated invariant t cells
US20190382725A1
Ion generation device and electric apparatus equipped with same
WO2014069072A1
Porous acoustic phase mask
WO2019180270A1
